7 registrations that name L-Serine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 7 registrations
Status
Phase
4US sites across 4 states
1
2 to 4
5 to 19
20 or more
All 7 registrations
RecruitingNCT07466290
L-serine and Strength Training in the Elderly
No phase
University of Vienna
About 126 people
Starts Mar 2026 (estimated)
In plain words A study of L-Serine in people 65 to 85, run by University of Vienna. It plans to enroll about 126 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 65 to 85; healthy volunteers accepted. Conditions: Brain Health; Longevity; Cognitive Performance; Strength Training Effects; Healthy Ageing; Ageing; Cognition; Memory; Muscle Strength.
Men and women between the ages of 65 and 85
Mini-Mental-State >23
Independently mobile, without aids (walker, cane, etc.)
The exclusion criteria are on the listing.
What it tests, as registered
Strength training; L-serine supplementation; Control (cornstarch)
Registered summary
This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people. Healthy, independent women and men aged 65 to 85 are eligible to participate. Participants will be randomly assigned to one of three groups: placebo, L-serine, or L-serine combined with strength training. Cognitive tests, physical performance tests, and blood and brain tests will be conducted over a period of 48 weeks. The full summary is on the listing.
Where, as registered
No US site; Austria (1).
RecruitingNCT07312110
D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression
Phase 2
Haukeland University Hospital
About 100 people
Started Jan 20, 2026
In plain words A Phase 2 study of L-Serine in people 40 to 80, run by Haukeland University Hospital. It plans to enroll about 100 people at 11 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 80. Conditions: Parkinson s Disease; Parkinson Disease (PD).
A clinical diagnosis of PD* according to the clinically established MDS clinical diagnostic criteria for Parkinson's disease within 5 years.
\[¹²³I\]FP-CIT single photon emission CT (DaTscan) confirming dopaminergic nigrostriatal denervation.
Hoehn and Yahr score < 3 at enrollment.
Optimal symptomatic PD treatment, not requiring adjustments, for at least 2 weeks.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
D-serine; Placebo
Registered summary
This clinical study, designed as a randomized, double-blind, placebo-controlled trial, aims to investigate if modulation of the N-methyl-D-aspartate receptor (NMDAR) via its co-agonist D-serine has therapeutic benefits in Parkinson's disease (PD). All patients will receive both placebo and D-serine over different time periods during the study. Preclinical studies have shown that blocking glycine transporters, which elevates endogenous glycine levels, can restore NMDAR function and improve motor deficits in PD models. The full summary is on the listing.
Where, as registered
No US site; Norway (11).
RecruitingNCT07497347
Effects of Specific Amino Acid Supplementation and Lifestyle Factors on Brain Ageing
No phase
IRCCS Centro San Giovanni di Dio Fatebenefratelli
About 84 people
Started Mar 1, 2026
In plain words A study of L-Serine in people 65 to 85, run by IRCCS Centro San Giovanni di Dio Fatebenefratelli. It plans to enroll about 84 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 65 to 85. Conditions: Late-Life Depression.
Age 65-85 years;
Presence of depressive symptoms, defined as a score ≥ 5 on the Geriatric Depression Scale-15 items (GDS-15) or ≥ 5 on the Patient Health Questionnaire-9 (PHQ-9).
The exclusion criteria are on the listing.
What it tests, as registered
L-serine supplementation; Placebo
Registered summary
The aim of this clinical trial is to investigate the effects of L-serine supplementation on cognitive decline and psychosocial functioning in older adults with late-life depression (LLD). The study will evaluate changes in depressive symptoms, neural and cognitive functioning, and will assess neurophysiological, metagenomic, and biochemical alterations associated with L-serine supplementation compared with placebo. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
RecruitingNCT07377032
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
Phase 3
Meyer Children's Hospital IRCCS
About 40 people
Started Aug 29, 2025
In plain words A Phase 3 study of L-Serine in people 2 to 30, run by Meyer Children's Hospital IRCCS. It plans to enroll about 40 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 2 to 30. Conditions: GRIN-related Disorders; GRIN1; GRIN2A; GRIN2B; GRIN2D; Epilepsy; Neurodevelopmental Disorder (Diagnosis).
Clinical diagnosis of a GRIN-related neurodevelopmental disorder (GRIN-NDD)
Presence of a pathogenic or likely pathogenic loss-of-function (LoF) variant in GRIN1, GRIN2A, GRIN2B, or GRIN2D
Parent(s), caregiver(s), or legally authorised representative(s) have been informed of the nature of the study and have provided written informed consent.
Participants who are able to do so have provided written informed consent or assent, according to local regulations and cognitive capacity.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
L-serine; Maltodextrin (Placebo)
Registered summary
The goal of this clinical study is to find out whether L-serine dietary supplementation helps improve overall clinical functioning in children and young adults (2-30 years) with GRIN-related neurodevelopmental disorders (GRIN-NDD) caused by loss-of-function (LoF) variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D. It will also assess the safety and tolerability of L-serine. The full summary is on the listing.
Where, as registered
No US site; France (1), Italy (1), Poland (1).
Not yet recruitingNCT07342439
Study of Serine Supplementation to Protect Vision in MacTel
Phase 3
The Lowy Medical Research Institute Limited
About 120 people
Starts Sep 2026 (estimated)
In plain words A Phase 3 study of L-Serine in people 18 and older, run by The Lowy Medical Research Institute Limited. It plans to enroll about 120 people at 12 sites, 4 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Macular Telangiectasia Type 2 (MacTel).
Be able to read, comprehend, and agree to conditions as explained in the informed consent document and provide written informed consent;
Be at least 18 years of age;
Enrolled or enrolling in the Natural History Observation and Registry Study (NHOR) and confirmed with MacTel type 2 by the Reading Center in at least one eye*;
Participant has clear ocular media (both eyes) for sufficient image quality;
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
L-serine; Placebo
Registered summary
The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2. The main questions it aims to answer are: * Does serine slow the progression of MacTel? * Is long-term serine supplementation safe in people with MacTel? Researchers will compare serine to a placebo (a look-alike substance that contains no drug) to see if serine works to slow the progression of MacTel. The full summary is on the listing.
Where, as registered
4 US sites in 4 states; also Germany (3), Australia (2), United Kingdom (2), Netherlands (1).
Not yet recruitingNCT07811076
Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer
Phase 1 and 2
Xuelei Ma MD
About 140 people
Starts Aug 31, 2026 (estimated)
In plain words A Phase 1 and 2 study of L-Serine in people 18 to 80, run by Xuelei Ma MD. It plans to enroll about 140 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Locally Advanced Rectal Cancer (LARC).
Written informed consent obtained prior to any study-related procedures.
Male or female, aged 18-80 years.
Histologically confirmed locally advanced rectal cancer staged as cT3, cT4, or node-positive by pelvic MRI.
ECOG performance status score of 0 or 1.
6 more inclusion criteria and the exclusion criteria are on the listing.
This is a Phase Ib/II seamless, open-label, randomized controlled trial evaluating the safety and efficacy of a serine/glycine-restricted diet combined with neoadjuvant chemoradiotherapy and immunotherapy in patients with locally advanced rectal cancer (LARC). The study consists of two phases. Phase Ib is a non-randomized, single-arm safety run-in phase enrolling 6 patients, all of whom will receive the experimental regimen (serine/glycine-restricted diet plus CAPOX chemotherapy, PD-1 inhibitor, and short-course radiotherapy). The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07178613
Assessment of the Dose Safety and Efficacy of Serine Combined With Fluorouracil Drugs
Phase 1
The First Affiliated Hospital of Xinxiang Medical College
About 20 people
Starts Nov 2025 (estimated)
In plain words A Phase 1 study of L-Serine in people 18 and older, run by The First Affiliated Hospital of Xinxiang Medical College. It plans to enroll about 20 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Advanced Colorectal Cancer.
Age ≥ 18 years (inclusive), male or female;
Patients with advanced colorectal cancer confirmed by histopathological or cytological examination, eligible for standard first-line treatment with fluorouracil-containing regimens.
Patients must have at least one measurable lesion.
ECOG performance status ≤ 2.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Serine（Oral）; Fluoropyrimidine Drugs
Registered summary
This study evaluates the dose safety and efficacy of serine in combination with fluoropyrimidine-based therapies. Primary objective: To determine the safety of oral serine administration. Secondary objectives: 1. To assess the preliminary efficacy of serine in the study population. 2. To establish the recommended Phase 2 dose for oral serine.